Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

McMeekin, 2004, Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer, Gynecol Oncol, 95, 157, 10.1016/j.ygyno.2004.07.008 Herzog, 2003, Workshop: options for therapy in ovarian cancer, Gynecol Oncol, 90, S45, 10.1016/S0090-8258(03)00473-6 Aghajanian, 2012, OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer, J Clin Oncol, 30, 2039, 10.1200/JCO.2012.42.0505 Ledermann, 2012, Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer, N Engl J Med, 366, 1382, 10.1056/NEJMoa1105535 Mirza, 2016, Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, N Engl J Med, 375, 2154, 10.1056/NEJMoa1611310 Coleman, 2017, Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial, Lancet Oncol, 18, 779, 10.1016/S1470-2045(17)30279-6 Ledermann, 2016, Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet, 387, 1066, 10.1016/S0140-6736(15)01167-8 Pujade-Lauraine, 2017, Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Oncol, 18, 1274, 10.1016/S1470-2045(17)30469-2 Kristeleit, 2017, A phase I–II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors, Clin Cancer Res, 23, 4095, 10.1158/1078-0432.CCR-16-2796 Swisher, 2017, Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial, Lancet Oncol, 18, 75, 10.1016/S1470-2045(16)30559-9 Watkins, 2014, Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers, Breast Cancer Res, 16, 211, 10.1186/bcr3670 Abkevich, 2012, Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer, Br J Cancer, 107, 1776, 10.1038/bjc.2012.451 Pedersen, 2013, Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients, Genes Chromosomes Cancer, 52, 794, 10.1002/gcc.22075 Marquard, 2015, Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs, Biomark Res, 3, 9, 10.1186/s40364-015-0033-4 Eisenhauer, 2009, New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Rustin, 2011, Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG), Int J Gynecol Cancer, 21, 419, 10.1097/IGC.0b013e3182070f17 Jensen, 2011, A new index of priority symptoms in advanced ovarian cancer, Gynecol Oncol, 120, 214, 10.1016/j.ygyno.2010.09.025 Brown, 1999, The Medical Dictionary for Regulatory Activities (MedDRA), Drug Saf, 20, 109, 10.2165/00002018-199920020-00002 Rahma, 2013, Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials, Ann Oncol, 24, 1972, 10.1093/annonc/mdt166 Westfall, 2001, Optimally weighted, fixed sequence and gatekeeper multiple testing procedures, J Stat Plan Inf, 99, 25, 10.1016/S0378-3758(01)00077-5 Temple, 2006, Hy's law: predicting serious hepatotoxicity, Pharmacoepidemiol Drug Saf, 15, 241, 10.1002/pds.1211 2017 2017 McCormick, 2017, In vitro assessment of the roles of drug transporters in the disposition and drug–drug interaction potential of olaparib, Xenobiotica, 47, 903, 10.1080/00498254.2016.1241449 Kikuchi, 2013, Prediction of clinical drug–drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K), J Pharm Sci, 102, 4426, 10.1002/jps.23737 Konecny GE, Oza AM, Tinker AV, et al. Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Annual Meeting on Women's Cancer 2017; National Harbor, USA; March 12–15, 2017. abstract 1. Oaknin A, Oza A, Tinker AV, et al. Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC). ECCO2017: European Cancer Congress; Amsterdam, Netherlands; Jan 27–30, 2017. Abstract 710. Ledermann, 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, Lancet Oncol, 15, 852, 10.1016/S1470-2045(14)70228-1